|
Miltenyi Biotec
anti cd196 pe clone rea190 mab ![]() Anti Cd196 Pe Clone Rea190 Mab, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/ccr6+antibody/CD196+(CCR6)+Antibody%2C+anti-human%2C+REAfinity/10__1016_slash_j__jff__2019__103495-119-18-31 Average 94 stars, based on 1 article reviews
anti cd196 pe clone rea190 mab - by Bioz Stars,
2026-11
94/100 stars
|
Buy from Supplier |
|
R&D Systems
ccr6 monoclonal antibody 53103 ![]() Ccr6 Monoclonal Antibody 53103, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/ccr6+antibody/CCR6+Antibody+(53103R)+%5BAllophycocyanin%5D/pmc00521846-116-67-73 Average 94 stars, based on 1 article reviews
ccr6 monoclonal antibody 53103 - by Bioz Stars,
2026-11
94/100 stars
|
Buy from Supplier |
|
R&D Systems
ccr6 antibody ![]() Ccr6 Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/ccr6+antibody/CCR6+Antibody/pmc04613941-61-15-17 Average 92 stars, based on 1 article reviews
ccr6 antibody - by Bioz Stars,
2026-11
92/100 stars
|
Buy from Supplier |
|
R&D Systems
ccr6 fab590p ![]() Ccr6 Fab590p, supplied by R&D Systems, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/ccr6+antibody/Human%2FMouse+CCR6+PE-conjugated+Antibody/pmc04326561__NIHMS617428___supplement___01-3-80-84 Average 91 stars, based on 1 article reviews
ccr6 fab590p - by Bioz Stars,
2026-11
91/100 stars
|
Buy from Supplier |
|
R&D Systems
rat anti mouse ccr6 ![]() Rat Anti Mouse Ccr6, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/ccr6+antibody/Mouse+CCR6+Antibody/pm19234209-89-9-12 Average 92 stars, based on 1 article reviews
rat anti mouse ccr6 - by Bioz Stars,
2026-11
92/100 stars
|
Buy from Supplier |
|
R&D Systems
anti mouse ccr6 monoclonal antibody ![]() Anti Mouse Ccr6 Monoclonal Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/ccr6+antibody/Mouse+CCR6+Antibody/pmc03511632-119-9-16 Average 94 stars, based on 1 article reviews
anti mouse ccr6 monoclonal antibody - by Bioz Stars,
2026-11
94/100 stars
|
Buy from Supplier |
|
R&D Systems
human ccr6 antibodies ![]() Human Ccr6 Antibodies, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/ccr6+antibody/Human+CCR6+Antibody/pmc04322653-61-17-25 Average 94 stars, based on 1 article reviews
human ccr6 antibodies - by Bioz Stars,
2026-11
94/100 stars
|
Buy from Supplier |
|
R&D Systems
mtc population with anti ccr6 ![]() Mtc Population With Anti Ccr6, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/ccr6+antibody/Human+CCR6+Antibody/pm11120783-49-8-16 Average 94 stars, based on 1 article reviews
mtc population with anti ccr6 - by Bioz Stars,
2026-11
94/100 stars
|
Buy from Supplier |
|
R&D Systems
anti ccr6 ![]() Anti Ccr6, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/ccr6+antibody/Rat+CCR6+Antibody/pm11994492-74-6-7 Average 90 stars, based on 1 article reviews
anti ccr6 - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
R&D Systems
anti ccr6 mab ![]() Anti Ccr6 Mab, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/ccr6+antibody/CCR6+Antibody+(1011306)+%5BFITC%5D/pm21178014-45-28-30 Average 94 stars, based on 1 article reviews
anti ccr6 mab - by Bioz Stars,
2026-11
94/100 stars
|
Buy from Supplier |
|
Proteintech
anti ccrl2 antibody ![]() Anti Ccrl2 Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/ccr6+antibody/CCRL2+Antibody/pmc06916697-70-4-10 Average 92 stars, based on 1 article reviews
anti ccrl2 antibody - by Bioz Stars,
2026-11
92/100 stars
|
Buy from Supplier |
|
R&D Systems
ccr6 ![]() Ccr6, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/ccr6+antibody/Mouse+CCR6+Alexa+Fluor%C2%AE+405-conjugated+Antibody/pm34803672-81-37-39 Average 90 stars, based on 1 article reviews
ccr6 - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
Image Search Results
Journal: Journal of Functional Foods
Article Title: Membrane vesicles from the probiotic Nissle 1917 and gut resident Escherichia coli strains distinctly modulate human dendritic cells and subsequent T cell responses
doi: 10.1016/j.jff.2019.103495
Figure Lengend Snippet: Fig. 6. Quantification of the Th17 and Treg subsets induced by MV-stimulated DCs. (A-B) Flow cytometric analysis of CD4+ T cells co-incubated for 3 days with untreated mo-DCs (iDC) or mo-DCs primed with MVs of the indicated strains (10 μg/ml) at a DC:T cell ratio of 1:5 with specific markers for: (A) Th17 population (CD4+ CD196+) and (B) Treg (CD25+(High) FoxP3+) population. Representative dot plots of CD4+ cells co-incubated with iDCs (control) or with EcN MV- stimulated DCS are shown for each cell subset analysis. The percentage of positive cells is indicated in each quadrant or box. (C) Data (mean ± SEM) from three- independent experiments performed in triplicate are expressed as fold-change increase in the percentage of positive T cells for Th17 or Treg specific markers induced by MV-stimulated DCs with respect control iDCs induced values (set as 1, dot line). Statistical differences were evaluated by one-way ANOVA followed by Bonferroni’s test (normal distribution) *p < 0.05 versus control DCs.
Article Snippet: For surface marker staining, lymphocytes were first stained with anti-CD4 FITC (clone VIT4), anti-CD25 APC (clone 4E3) and
Techniques: Incubation, Control
Journal:
Article Title: Maturation and Trafficking Markers on Rotavirus-Specific B Cells during Acute Infection and Convalescence in Children
doi: 10.1128/JVI.78.20.10967-10976.2004
Figure Lengend Snippet: Representative flow cytometry analysis of large IgD− B cells from acutely infected children (left lower dot plots) and children in convalescence (right lower dot plots) for the expression of the indicated maturation markers. B cells were negatively selected with magnetic beads and then stained with monoclonal antibodies against IgD, α4β7, CD38, CD27, or CCR6 and with GFP-VLP. For analysis, cells were gated on large (top left dot plot), IgD− (top right dot plot) lymphocytes. Based on this subpopulation, the lower dot plots were created showing expression of CCR6, CD38, and CD27 and GFP-VLP fluorescence. The percentages of IgD− GFP-VLP+ (RV-sIg) cells expressing each marker are indicated in the right quadrants.
Article Snippet: Then the cells were washed with PBS-0.5% bovine serum albumin (Sigma)-0.02% sodium azide (Mallinckrodt Chemicals, Paris, Ky.) (staining buffer) and stained with different combinations of monoclonal antibodies against the following human proteins: α4β7 phycoerythrin-conjugated monoclonal antibody Act-1, mouse IgG1 (Charles Mackay Leukosite Inc., Cambridge, Mass.); purified CCR10 monoclonal antibody 1B5, mouse IgG2a (Millenium Pharmaceuticals Inc., Cambridge, Mass.); purified CCR9 monoclonal antibody 96-1, mouse IgG1 (Millenium Pharmaceuticals); purified
Techniques: Flow Cytometry, Infection, Expressing, Magnetic Beads, Staining, Fluorescence, Marker
Journal:
Article Title: Maturation and Trafficking Markers on Rotavirus-Specific B Cells during Acute Infection and Convalescence in Children
doi: 10.1128/JVI.78.20.10967-10976.2004
Figure Lengend Snippet: Mean and standard error of the mean of IgD− (a) and IgD− RV-sIg (b) large B cells that express the maturation markers CD38high, CD27high and CCR6 in children during acute infection (n = 6 to 12 children) and convalescence (n = 4 to 8 children). The frequencies of cells expressing each marker in individual children were obtained as described for Fig. Fig.2.2. *, significant differences between acute infection and convalescence for each marker (P < 0.01, Mann-Whitney test).
Article Snippet: Then the cells were washed with PBS-0.5% bovine serum albumin (Sigma)-0.02% sodium azide (Mallinckrodt Chemicals, Paris, Ky.) (staining buffer) and stained with different combinations of monoclonal antibodies against the following human proteins: α4β7 phycoerythrin-conjugated monoclonal antibody Act-1, mouse IgG1 (Charles Mackay Leukosite Inc., Cambridge, Mass.); purified CCR10 monoclonal antibody 1B5, mouse IgG2a (Millenium Pharmaceuticals Inc., Cambridge, Mass.); purified CCR9 monoclonal antibody 96-1, mouse IgG1 (Millenium Pharmaceuticals); purified
Techniques: Infection, Expressing, Marker, MANN-WHITNEY
Journal:
Article Title: Maturation and Trafficking Markers on Rotavirus-Specific B Cells during Acute Infection and Convalescence in Children
doi: 10.1128/JVI.78.20.10967-10976.2004
Figure Lengend Snippet: Coexpression of maturation markers and trafficking receptors on large IgD− RV-sIg B cells. Shown are representative experiments of the study of the coexpression of CD38 and CD27 (a) and CD38, CCR6, CCR9, CCR10, and α4β7 (b) on large IgD− RV-sIg B cells from children during acute infection (left dot plots) and convalescence (right dot plots). Analysis was done with the basic strategy described for Fig. Fig.2.2. Dot plots show expression of each indicated marker and/or receptor on cells with a gate on large IgD− RV-sIg B cells. The percentages of cells in all the quadrants are indicated.
Article Snippet: Then the cells were washed with PBS-0.5% bovine serum albumin (Sigma)-0.02% sodium azide (Mallinckrodt Chemicals, Paris, Ky.) (staining buffer) and stained with different combinations of monoclonal antibodies against the following human proteins: α4β7 phycoerythrin-conjugated monoclonal antibody Act-1, mouse IgG1 (Charles Mackay Leukosite Inc., Cambridge, Mass.); purified CCR10 monoclonal antibody 1B5, mouse IgG2a (Millenium Pharmaceuticals Inc., Cambridge, Mass.); purified CCR9 monoclonal antibody 96-1, mouse IgG1 (Millenium Pharmaceuticals); purified
Techniques: Infection, Expressing, Marker
Journal: Journal of immunology (Baltimore, Md. : 1950)
Article Title: Inhibition of CCR6 function reduces the severity of experimental autoimmune encephalomyelitis via effects on the priming phase of the immune response.
doi: 10.4049/jimmunol.0713169
Figure Lengend Snippet: FIGURE 1. Changes in the expression of CCR6 on CD4 cells. Mice were immunized to induce EAE and fed BrdU starting on day 6 postim- munization. Spinal cord and draining LN were collected on days 9, 12, and 21 postimmunization. Within the CD4 T cell population, the percentage of BrdU (divided) and BrdU (undivided) cells expressing CCR6 was determined as a proportion of the total BrdU and BrdU populations. Data are presented as means SEM (n 5).
Article Snippet: The remaining whole blood was then double labeled with
Techniques: Expressing
Journal: Journal of immunology (Baltimore, Md. : 1950)
Article Title: Inhibition of CCR6 function reduces the severity of experimental autoimmune encephalomyelitis via effects on the priming phase of the immune response.
doi: 10.4049/jimmunol.0713169
Figure Lengend Snippet: FIGURE 2. CCR6 has a pathogenic role in neuroinflammation. A, Wild- type (n 10) and CCR6 knockout mice (n 9) were immunized with 100 g of MOG35–55 in CFA to induce EAE, and CCR6 knockout mice showed significantly lower disease scores during disease progression. B and C, Cumulative disease scores and mean maximum disease scores for the ex- periment shown in A. Results shown are means SEM. , p 0.05.
Article Snippet: The remaining whole blood was then double labeled with
Techniques: Knock-Out, Biomarker Discovery
Journal: Journal of immunology (Baltimore, Md. : 1950)
Article Title: Inhibition of CCR6 function reduces the severity of experimental autoimmune encephalomyelitis via effects on the priming phase of the immune response.
doi: 10.4049/jimmunol.0713169
Figure Lengend Snippet: FIGURE 3. Development and characterization of a CCR6 antagonist. A, Amino acid sequence of wild-type and mutant forms of CCL20 used in this study. B, Dose- response curve of LPS-stimulated murine splenocytes to CCL20 and the synthetic truncated peptides CCL20(4–70), CCL20(A4–70), CCL20(5–70), and CCL20(6–70). C, The inhibition of CCL20-mediated chemotaxis of LPS-stim- ulated murine splenocytes (60 ng/ml) by synthetic trun- cated CCL20 peptides. Data are presented as means SEM (B, n 5; C, n 6). D, In two independent experiments, mice were injected i.p. with 100 g of CCL20(6–70) or the control peptide CCL2(4Ala) on days 1, 3, 5, 7, 9, 11, 13, and 15 postinduction of EAE. Re- sults were pooled from individual experiments to pro- duce data points representing means SEM (n 18). Individual experimental results are listed in Table I. , p 0.05.
Article Snippet: The remaining whole blood was then double labeled with
Techniques: Sequencing, Mutagenesis, Inhibition, Chemotaxis Assay, Injection, Control
Journal: Journal of immunology (Baltimore, Md. : 1950)
Article Title: Inhibition of CCR6 function reduces the severity of experimental autoimmune encephalomyelitis via effects on the priming phase of the immune response.
doi: 10.4049/jimmunol.0713169
Figure Lengend Snippet: FIGURE 4. Treatment with CCL20(6–70) reduces the histopathology in the CNS, and treatment with CCL20(6–70) or CCR6 deletion reduces infiltration of CD4 T cells into the spinal cord during EAE. Representative transverse spinal cord sections labeled for CD45 (diaminobenzidine) with hematoxylin counterstain from naive mice (A and B), EAE mice pretreated with CCL2(4Ala) (C and D), and EAE mice pretreated with CCL20(6–70) (E and F). Spinal cords were collected on day 14 postinduction of EAE. These sections are from mice with disease scores of 2.25 (C and D) and 0.5 (E and F). Magnification 25 (A, C, and F), 100 (B, D, and F). The data are representative of 10 sections each from three mice. The number of lesions (see arrows in C and E) visible from each section was quantified (G). Ten sections from three mice were analyzed and the results shown are the means SEM. , p 0.0001. Lesions were defined as accumulations of 10 CD45 cells. The number of CD4 T cells recovered from the spinal cord of SJL/J mice on day 12 of PLP139–151-induced EAE pretreated with CCL2(4Ala) or CCL20(6–70) were enumerated by flow cytometry (H). Data shown are the mean numbers of CD4 T cells SEM. , p 0.05. The number of CD4 T cells recovered from the spinal cords of CCR6/ or wild-type C57BL/6 mice on day 16 of MOG35–55-induced EAE were quantified by flow cytometry (I). Data shown are the mean numbers of CD4 T cells SEM. , p 0.01.
Article Snippet: The remaining whole blood was then double labeled with
Techniques: Histopathology, Labeling, Cytometry
Journal: Journal of immunology (Baltimore, Md. : 1950)
Article Title: Inhibition of CCR6 function reduces the severity of experimental autoimmune encephalomyelitis via effects on the priming phase of the immune response.
doi: 10.4049/jimmunol.0713169
Figure Lengend Snippet: FIGURE 5. Characterization of neutralizing anti-CCR6 Abs and their effect on the development of EAE. A, Inhibition of CCL20-mediated che- motaxis by rabbit anti-CCR6 Abs but not NRIgG. B, Rabbit anti-murine CCR6 Abs do not induce cellular migration in vitro compared with random chemokinesis. A, n 16 for anti-CCR6 Abs, n 5 for NRIgG; B, n 4. C, In two independent experiments, mice were injected with 100 g of affinity-purified rabbit anti-mouse CCR6 Abs or NRIgG 24 h before dis- ease induction. Results were pooled from individual experiments to pro- duce data points representing means SEM (n 13). , p 0.05. Indi- vidual experimental results are listed in Table I.
Article Snippet: The remaining whole blood was then double labeled with
Techniques: Inhibition, Migration, In Vitro, Injection
Journal: Journal of immunology (Baltimore, Md. : 1950)
Article Title: Inhibition of CCR6 function reduces the severity of experimental autoimmune encephalomyelitis via effects on the priming phase of the immune response.
doi: 10.4049/jimmunol.0713169
Figure Lengend Snippet: FIGURE 6. Lack of effect of CCR6 inhibition on adoptive transfer of EAE. Donor mice were immunized with PLP139–151. Ten days postimmu- nization, draining LN cells were restimulated for 4 days in vitro with 50 g/ml PLP139–151, and 5 107 cells were transferred into naive recipients that had been treated with 100 g of either (A) CCL20(6–70) or the control peptide CCL2(4Ala) on days 1, 3, 5, 7, 9, 11, 13, and 15 posttransfer or (B) affinity-purified rabbit anti-mouse CCR6 Abs or NRIgG 24 h before trans- fer (pooled from two independent experiments). Data are presented as mean clinical disease scores SEM (n 6 for each experimental group in A, 12 in B).
Article Snippet: The remaining whole blood was then double labeled with
Techniques: Inhibition, Adoptive Transfer Assay, In Vitro, Control
Journal: Journal of immunology (Baltimore, Md. : 1950)
Article Title: Inhibition of CCR6 function reduces the severity of experimental autoimmune encephalomyelitis via effects on the priming phase of the immune response.
doi: 10.4049/jimmunol.0713169
Figure Lengend Snippet: FIGURE 8. Effect of CCL20(6–70) treatment or CCR6 deficiency on the migration of DCs to draining LNs during EAE induction. Mice were in- jected with either CCL20(6–70), CCL21(8–110), or CCL2(4Ala) i.p. 1 h before immunization with CFA/PLP s.c. in each flank. At 48 (A) and 96 h (B) postimmunization, inguinal LNs were removed, single-cell suspensions prepared, and CD11c DCs positively selected and enumerated. Data are presented as means SEM (n 14 for each experimental group). , p 0.05. C, The same approach was used to evaluate the migration of CD11C
Article Snippet: The remaining whole blood was then double labeled with
Techniques: Migration
Journal: Journal of immunology (Baltimore, Md. : 1950)
Article Title: Inhibition of CCR6 function reduces the severity of experimental autoimmune encephalomyelitis via effects on the priming phase of the immune response.
doi: 10.4049/jimmunol.0713169
Figure Lengend Snippet: FIGURE 10. Treatment with CCL20(6–70) results in fewer circulating CD4/CCR6 lymphocytes after Ag priming, before disease onset. Blood was collected from day 9 EAE mice pretreated with either CCL20(6–70) or CCL2(4Ala), and the percentage of circulating CD4/CCR6 lymphocytes was determined by flow cytometric analysis. A, Data are presented as mean percentage of blood SEM (n 6 for each experimental group). , p 0.0001. A representative dot plot showing CD4 and CCR6 staining on lymphocyte-gated peripheral blood cells is shown in B.
Article Snippet: The remaining whole blood was then double labeled with
Techniques: Staining
Journal: The Journal of investigative dermatology
Article Title: CCR6 is required for epidermal trafficking of γδ T cells in an IL-23-induced model of psoriasiform dermatitis
doi: 10.1038/jid.2012.260
Figure Lengend Snippet: Following treatment with neutralizing anti-CCL20 mAb, isotype control, or PBS injection for 5 days, both pooled epidermal ( a ) and dermal ( b ) cell suspensions from 4 mouse ears (per condition) were stained with mAbs against γδ TCR for flow cytometry e( a,b ) or processed for RNA extraction for RT-PCR ( c,d ). In ( a,b ), the percentage indicated in each dot plot reflects the number of GDL cells (i.e., events) in the oval window divided by the total sample events shown in the entire dot plot. Percent reduction in epidermal GDL T cells was calculated at 76% for data shown [(% GDL cells IL23 + isotype)-(% GDL cells IL23+anti-CCL20)]/[(%GDL cells IL23+isotype)-(%GDL cells PBS)]*100. Pooled epidermal ( c ) and dermal ( d ) cell suspensions (see above) were used for quantitative RT-PCR to measure expression of IL-22 and CCR6. Fold changes were calculated for IL-22 and Ccr6 mRNAs normalized for Gapdh mRNA vs . the PBS treated sample. Error bars indicate SD ( c,d ) based on a single, pooled treatment group that was divided into three wells for RT-PCR measurement. Similar results were obtained in 2 independent experiments.
Article Snippet: After washing in PBS, tissue sections were incubated with
Techniques: Control, Injection, Staining, Flow Cytometry, RNA Extraction, Reverse Transcription Polymerase Chain Reaction, Quantitative RT-PCR, Expressing
Journal: The Journal of investigative dermatology
Article Title: CCR6 is required for epidermal trafficking of γδ T cells in an IL-23-induced model of psoriasiform dermatitis
doi: 10.1038/jid.2012.260
Figure Lengend Snippet: Following IL-23 ( a ) or PBS ( b ) injection for 6 days, mice were euthanized and ears were stained with anti-CCR6 mAbs (green) and anti-Laminin 332 mAbs (basement membrane in red), and the 3D images were acquired using a confocal microscope. The figure shows the perspective from the dermis toward the epidermis. The width of basement membrane in red shows the depth of the sections. Larger numbers of CCR6-expressing cells in the epidermis (above the basement membrane) were revealed in IL-23-, but not PBS-injected, mice. CCR6-expressing cells ( a ) at (arrow head), immediately adjacent to (double arrowheads), or above (arrow) the basement membrane in the dashed rectangular area marked in the upper figure are shown at higher magnification below. Isotype control staining showed no staining with either IL-23 or PBS-injected ears (data not shown). Scale bar = 10 μm. In ( c ), IL-23-treated skin sections were stained with labeled mAbs against CCR6 (green) and the γδ-TCR (red). Images were acquired by confocal microscopy at the level of the epidermis (x63 objective, scale bar as indicated). Similar results were obtained in 3 independent experiments.
Article Snippet: After washing in PBS, tissue sections were incubated with
Techniques: Injection, Staining, Membrane, Microscopy, Expressing, Control, Labeling, Confocal Microscopy
Journal: The Journal of investigative dermatology
Article Title: CCR6 is required for epidermal trafficking of γδ T cells in an IL-23-induced model of psoriasiform dermatitis
doi: 10.1038/jid.2012.260
Figure Lengend Snippet: Following IL-23 injection for 6 days, both WT and CCR6 KO mice were euthanized. Both epidermal and dermal cell suspensions were analyzed by flow cytometry with γδ TCR, CD3, and IL-22 mAbs. ( a ) Total numbers of GDL T cells per PBS- or IL-23-injected ear of WT and CCR6 KO mice were counted. The percentages of CD3 + GDL T cells ( b ) and IL-22 + GDL T cells ( c ) were calculated. *P<0.01 vs. all other groups. **P<0.05 vs. all other groups. Each treatment group consisted of 4 ears. All P values were calculated using Student’s t-test, 2-sided. In ( c , epidermis), p values are provided for comparisons between PBS and IL-23-treatment in WT and CCR6 KO mice. Similar results were obtained in 2 independent experiments.
Article Snippet: After washing in PBS, tissue sections were incubated with
Techniques: Injection, Flow Cytometry
Journal: Gastroenterology Research and Practice
Article Title: The Increased Expression of CCL20 and CCR6 in Rectal Mucosa Correlated to Severe Inflammation in Pediatric Ulcerative Colitis
doi: 10.1155/2015/856532
Figure Lengend Snippet: Immunohistochemical findings for CCR6 in the rectal mucosa. CCR6 expression was observed in the nucleus or cytoplasm of epithelial cells, infiltrating inflammatory cells, and endothelial cells. Different grades of CC6 infiltrating pattern in epithelia were evaluated as follows: grade 0 (negative, (a)), 38 specimens; grade 1 (focal, (b)), 59 specimens; grade 2 (diffuse, (c)), 44 specimens, respectively. Original magnification, 100x.
Article Snippet: Human CCL20/MIP-3 α antibodies (monoclonal mouse IgG1 clone #67310, R&D Systems, USA; dilution: 1 : 250) and
Techniques: Immunohistochemical staining, Expressing
Journal: Gastroenterology Research and Practice
Article Title: The Increased Expression of CCL20 and CCR6 in Rectal Mucosa Correlated to Severe Inflammation in Pediatric Ulcerative Colitis
doi: 10.1155/2015/856532
Figure Lengend Snippet: The relationship between pathological inflammation severity and CCL20 and CCR6 expression.
Article Snippet: Human CCL20/MIP-3 α antibodies (monoclonal mouse IgG1 clone #67310, R&D Systems, USA; dilution: 1 : 250) and
Techniques: Expressing
Journal: Gastroenterology Research and Practice
Article Title: The Increased Expression of CCL20 and CCR6 in Rectal Mucosa Correlated to Severe Inflammation in Pediatric Ulcerative Colitis
doi: 10.1155/2015/856532
Figure Lengend Snippet: The comparison of CCL20 and CCR6 expression between CUC and AUC.
Article Snippet: Human CCL20/MIP-3 α antibodies (monoclonal mouse IgG1 clone #67310, R&D Systems, USA; dilution: 1 : 250) and
Techniques: Comparison, Expressing
Journal: Journal of immunology (Baltimore, Md. : 1950)
Article Title: CCL20 and β-defensin-2 induce arrest of human Th17 cells on inflamed endothelium in vitro under flow conditions.
doi: 10.4049/jimmunol.1000597
Figure Lengend Snippet: FIGURE 4. Specific ligand-mediated triggering of CCR6 induces CD11a/CD18-CD54–dependent arrest of differentiated Th17 cells on HUVEC, stimulated with IL-1b and TNF-a, in vitro under flow conditions. Fully differentiated human Th17 and Th2 clones (A–C) or purified CCR6+ and CCR62
Article Snippet: mAbs, flow cytometry analysis, and FACS sorting The following mAbs were used for immunostaining: FITC- or PE-conjugated anti-CD4 mAbs (BD Biosciences, Le Pont-De-Claix, France), a FITC- or PE-conjugated
Techniques: In Vitro, Clone Assay
Journal: Journal of immunology (Baltimore, Md. : 1950)
Article Title: CCL20 and β-defensin-2 induce arrest of human Th17 cells on inflamed endothelium in vitro under flow conditions.
doi: 10.4049/jimmunol.1000597
Figure Lengend Snippet: FIGURE 5. Calcium mobilization in CCR6-expressing CHO cells by CCL20 and hBD-2. CHO cells stably transfected with human CCR6 re- ceptor were loaded with Ca No Wash Plus Dye and stimulated with CCL20 and hBD-2. To study CCR6 receptor desensitization, 350 ng/ml CCL20 was added 60 s after the first stimulation. [Ca2+]i concentration was monitored by measuring fluorescence for 180 s on a fluorescence plate reader. A, Ki- netics study obtained with CCL20 and hBD-2 at 250 and 500 ng/ml final concentration, respectively. Arrowheads indicate time of application of each ligand. [Ca2+]i response was calculated as relative fluorescence units (RFU) minus background from each value. B, The inhibitory activity of hBD-2 (filled squares) and CCL20 (empty squares) was assayed at indicated con- centrations on calcium response elicited in CHO-CCR6 by 350 ng/ml CCL20. Data are representative of three independent experiments.
Article Snippet: mAbs, flow cytometry analysis, and FACS sorting The following mAbs were used for immunostaining: FITC- or PE-conjugated anti-CD4 mAbs (BD Biosciences, Le Pont-De-Claix, France), a FITC- or PE-conjugated
Techniques: Expressing, Stable Transfection, Transfection, Concentration Assay, Activity Assay
Journal: Journal of immunology (Baltimore, Md. : 1950)
Article Title: CCL20 and β-defensin-2 induce arrest of human Th17 cells on inflamed endothelium in vitro under flow conditions.
doi: 10.4049/jimmunol.1000597
Figure Lengend Snippet: FIGURE 6. Ag-specific activation results in downregulation of CCR6 mRNA and loss of CCR6 expression from the surface of Th17 cells. A Th17 cell clone was stimulated with the combination of anti-CD3 and anti-CD28 mAbs (A), or a PPD-specific CCR6-expressing T cell clone was stimulated with PPD and autologous monocytes (B), and the evolution of CCR6 expression at the cell surface was analyzed by flow cytometry. The x-axis represents fluorescence (four-decade log scale), and the y-axis represents the relative cell number. Values in histograms represent percentage of CCR6+ T cells and mean fluo- rescence intensity. Isotype-matched control mAb as in Fig. 4D. C, Cells, stimulated as under A, were collected at the indicated time interval after their activation, lysed, and CCR6 mRNA expression was determined by real-time PCR. Values represent mean 6 SD of three experiments.
Article Snippet: mAbs, flow cytometry analysis, and FACS sorting The following mAbs were used for immunostaining: FITC- or PE-conjugated anti-CD4 mAbs (BD Biosciences, Le Pont-De-Claix, France), a FITC- or PE-conjugated
Techniques: Activation Assay, Expressing, Cytometry, Control, Real-time Polymerase Chain Reaction
Journal: Journal of immunology (Baltimore, Md. : 1950)
Article Title: CCL20 and β-defensin-2 induce arrest of human Th17 cells on inflamed endothelium in vitro under flow conditions.
doi: 10.4049/jimmunol.1000597
Figure Lengend Snippet: FIGURE 7. Downregulation of CCR6 expression on Th17 cells is independent from endogenous CCL20 production. Th17 cells were incubated in medium only or in the presence of CCL20 (100 ng/ ml) or were activated with anti-CD3 and anti-CD28 mAb. CCR6 expression was analyzed at the indicated time periods by flow cytometry. A, Flow cytometry analysis data from a representative experiment. The x-axis represents fluorescence (four-decade log scale), and the y-axis represents the relative cell number. Values indicated in the upper right quadrants repre- sent the percentage 6 SD of CCR6-positive cells and their relative fluorescence intensity. B, Evolution of cell-surface CCR6 expression expressed as the rel- ative fluorescence intensity 6 SD obtained in three independent experiments.
Article Snippet: mAbs, flow cytometry analysis, and FACS sorting The following mAbs were used for immunostaining: FITC- or PE-conjugated anti-CD4 mAbs (BD Biosciences, Le Pont-De-Claix, France), a FITC- or PE-conjugated
Techniques: Expressing, Incubation, Cytometry, Flow Cytometry
Journal: OncoTargets and therapy
Article Title: Oncogenic Role and Prognostic Value of MicroRNA-937-3p in Patients with Breast Cancer
doi: 10.2147/OTT.S229510
Figure Lengend Snippet: miR-937-3p negatively regulates CCRL2 expression by directly targeting its 3ʹ UTR. Notes: Venn diagram of target genes for miR-937-3p predicted by targetscan and miRDB website ( A and B ). The predicted binding sites of miR-937-3p on the 3′UTR of CCRL2 and the mutant miR-937-3p sequence at the binding site ( C ). The miR-937-3p expression level in breast cancer tissues and adjacent normal breast tissues were compared using TCGA database ( D ) and GSE70905 database ( E ). Correlations between miR-937-3p and CCRL2 mRNA levels ( F ). The analysis of the relative luciferase activity of CCRL2-3′UTR plus miR-937-3p, CCRL2-3′UTR plus miR-937-3p Mut and CCRL2-3′UTR plus miR-937-3p-NC ( G ). Relative expression of CCRL2 protein in MCF-7 cells transfected with miR-937-3p mimics, miR-937-3p Mut or miR-937-3p-NC ( H and I ). **p<0.01; ***p<0.001. Abbreviation: NS, not significant.
Article Snippet: Anti-GAPDH antibody (60004-1-Ig) and
Techniques: Expressing, Binding Assay, Mutagenesis, Sequencing, Luciferase, Activity Assay, Transfection
Journal: OncoTargets and therapy
Article Title: Oncogenic Role and Prognostic Value of MicroRNA-937-3p in Patients with Breast Cancer
doi: 10.2147/OTT.S229510
Figure Lengend Snippet: miR-937-3p promotes cell proliferation, migration and invasion through regulating CCRL2 in breast cancer. Notes: The expression of CCRL2 in MCF-7 cells transfected with CCRL2-siRNA or CCRL2-siRNA-NC was determined by RT-qPCR ( A ) and western-blot ( B ). CCK8 and SRB assay were used to evaluate the proliferation of MCF-7 cells following transfection with miR-937-3p-inhibitor plus CCRL2-siRNA or CCRL2-siRNA-NC transfection ( C and D ). The migration ability of MCF-7 cells with miR-937-3p-inhibitor plus CCRL2-siRNA or CCRL2-siRNA-NC transfection ( E and F ). The invasion ability of MCF-7 cells with miR-937-3p-inhibitor plus CCRL2-siRNA or CCRL2-siRNA-NC transfection ( G and H ). **p<0.01; ***p<0.001.
Article Snippet: Anti-GAPDH antibody (60004-1-Ig) and
Techniques: Migration, Expressing, Transfection, Quantitative RT-PCR, Western Blot, Sulforhodamine B Assay
Journal: OncoTargets and therapy
Article Title: Oncogenic Role and Prognostic Value of MicroRNA-937-3p in Patients with Breast Cancer
doi: 10.2147/OTT.S229510
Figure Lengend Snippet: miR-937-3p is an unfavorable prognostic factor in breast cancer. Notes: The Kaplan–Meier survival analyses of miR-937-3p expression of the overall survival time in breast cancer patients using TCGA ( A ). The Kaplan–Meier survival analyses of CCRL2 expression of the overall survival time in breast cancer patients using GSE16446 based on the website of the Kaplan–Meier plotter ( B ).The Kaplan–Meier survival analyses of miR-937-3p low level and CCRL2 high level, miR-937-3p high level and CCRL2 low level and other (miR-937-3p low level and CCRL2 low level and miR-937-3p high level and CCRL2 high level) in breast cancer patients using TCGA ( C ).
Article Snippet: Anti-GAPDH antibody (60004-1-Ig) and
Techniques: Expressing
Journal: Frontiers in pharmacology
Article Title: Transgenic Overexpression of Galectin-3 in Pancreatic β Cells Attenuates Hyperglycemia in Mice: Synergistic Antidiabetic Effect With Exogenous IL-33.
doi: 10.3389/fphar.2021.714683
Figure Lengend Snippet: FIGURE 4 | Transgenically enhanced Gal-3 expression on β-cells decreases the percentage of pro-inflammatory cells in pancreatic islets. Phenotypic characteristics of cells in pancreatic islets. Percentage of pro-inflammatory and regulatory cells. The percentages and representative dot and contour plots of (A) CD4+ cells, (B) CD4+CXCR3+ cells, (C) CD4+CCR6+ cells, (D) CD8+ cells, (E) CD8+CXCR3+ cells (F) CD4+FoxP3+ cells, and (G) CD4+FoxP3+ST2+. Data from two individual experiments with at least 5–7 mice per group are shown as mean ± SD and compared by the paired t-test or Mann–Whitney test.
Article Snippet: Cells were labeled with fluorochrome-conjugated monoclonal antibodies: anti-mouse CD3 (FAB4841F, R&D Systems, Minneapolis, MN), CD4 (130-102-597, MACS Biotech and FAB554F, R&D Systems, Minneapolis, MN), CD8 (130-102-468, MACS Biotech, Bergisch Gladbach,, Germany and FAB116A, R&D Systems, Minneapolis, MN),
Techniques: Expressing, MANN-WHITNEY